Barrington analyst James Goss upgraded Cinemark Holdings to Outperform from Market Perform with a $15 price target. News of a successful vaccine test with more than 90% efficacy should be key to pushing up the time frame for which consumers will be willing to return to theatres, Goss tells investors in a research note. The analyst continues to view Cinemark as a “high-quality operator with a more sustainable balance sheet than some of its larger peers.” He believes today’s positive vaccine news is a “key trigger to accelerating a return to restoration of favorable business activity.”
previous post
next post